To include your compound in the COVID-19 Resource Center, submit it here.

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

ArcherDX picks deal with Invitae over IPO
Genetic testing company Invitae (NYSE:NVTA) is acquiring ArcherDX Inc., adding a cancer diagnostics platform to its precision oncology business. ArcherDX’s shareholders will receive $325 million in cash plus 30 million shares of Invitae stock; based on Friday’s close of $18.71, the equity component is worth $561.3 million. The shareholders are also eligible to receive another 27 million shares tied to milestones, bringing the deal’s potential value to $1.4 billion. This month,

Read the full 775 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE